{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:32:51Z","timestamp":1792650771749,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40263-022-00963-9","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:13:34Z","timestamp":1669162414000},"page":"1269-1283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson\u2019s Disease: A Systematic Review and Bayesian Network Meta-analysis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-2807","authenticated-orcid":false,"given":"Angelo","family":"Antonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6466","authenticated-orcid":false,"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-7478","authenticated-orcid":false,"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-5706","authenticated-orcid":false,"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-726X","authenticated-orcid":false,"given":"Aristide","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna L.","family":"Kandukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0720-7894","authenticated-orcid":false,"given":"Ali","family":"Alobaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1467-4666","authenticated-orcid":false,"given":"Connie H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Zadikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5613-6121","authenticated-orcid":false,"given":"Juan Carlos","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-0505","authenticated-orcid":false,"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"1","key":"963_CR1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung VSC, Lopiano L, Elibol B, Smolentseva IG, Seppi K, et al. Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19(1):50.","journal-title":"BMC Neurol"},{"key":"963_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.parkreldis.2018.03.027","volume":"52","author":"M Skorvanek","year":"2018","unstructured":"Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, et al. Relationship between the MDS-UPDRS and Quality of Life: a large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018;52:83\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"963_CR3","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/mds.22106","volume":"23","author":"P Martinez-Martin","year":"2008","unstructured":"Martinez-Martin P, Arroyo S, Rojo-Abuin JM, Rodriguez-Blazquez C, Frades B, de Pedro CJ, et al. Burden, perceived health status, and mood among caregivers of Parkinson\u2019s disease patients. Mov Disord. 2008;23(12):1673\u201380.","journal-title":"Mov Disord"},{"issue":"2","key":"963_CR4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11136-004-6253-y","volume":"14","author":"P Martinez-Martin","year":"2005","unstructured":"Martinez-Martin P, Benito-Leon J, Alonso F, Catalan MJ, Pondal M, Zamarbide I, et al. Quality of life of caregivers in Parkinson\u2019s disease. Qual Life Res. 2005;14(2):463\u201372.","journal-title":"Qual Life Res"},{"issue":"12","key":"963_CR5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063\u201373.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"963_CR6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","volume":"21","author":"P Odin","year":"2015","unstructured":"Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133\u201344.","journal-title":"Parkinsonism Relat Disord"},{"key":"963_CR7","doi-asserted-by":"crossref","unstructured":"Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the definition of advanced Parkinson's disease: a neurologists-based Delphi study (CEPA study). Parkinsons Dis. 2017;2017:4047392.","DOI":"10.1155\/2017\/4047392"},{"key":"963_CR8","unstructured":"AbbVie. Duodopa Intestinal Gel summary of product characteristics. 2014 26 June 2014 [cited 12 May 2015]; http:\/\/www.medicines.org.uk\/emc\/medicine\/20786. Accessed: Dec 2021."},{"issue":"2","key":"963_CR9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","volume":"15","author":"D Nyholm","year":"2013","unstructured":"Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease patients. AAPS J. 2013;15(2):316\u201323.","journal-title":"AAPS J"},{"key":"963_CR10","unstructured":"APO-go PFS 5 mg\/ml solution for infusion in pre-filled syringe summary of product characteristics. July 2018 [cited; Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3908\/smpc. Accessed: Dec 2021."},{"issue":"2","key":"963_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol"},{"issue":"9","key":"963_CR12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749\u201359.","journal-title":"Lancet Neurol"},{"issue":"1","key":"963_CR13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63\u201373.","journal-title":"JAMA"},{"issue":"4","key":"963_CR14","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3171\/2016.11.JNS16715","volume":"128","author":"A Mansouri","year":"2018","unstructured":"Mansouri A, Taslimi S, Badhiwala JH, Witiw CD, Nassiri F, Odekerken VJJ, et al. Deep brain stimulation for Parkinson\u2019s disease: meta-analysis of results of randomized trials at varying lengths of follow-up. J Neurosurg. 2018;128(4):1199\u2013213.","journal-title":"J Neurosurg"},{"key":"963_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2020.12.024","volume":"83","author":"R Katzenschlager","year":"2021","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Long-term safety and efficacy of apomorphine infusion in Parkinson\u2019s disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021;83:79\u201385.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"963_CR16","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","volume":"38","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Pahwa R, Aldred J, Alobaidi A, Jalundhwala YJ, et al. The long-term impact of levodopa\/carbidopa intestinal gel on \u2019off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review. Adv Ther. 2021;38(6):2854\u201390.","journal-title":"Adv Ther"},{"issue":"4","key":"963_CR17","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mds.23524","volume":"26","author":"A Merola","year":"2011","unstructured":"Merola A, Zibetti M, Angrisano S, Rizzi L, Lanotte M, Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson\u2019s disease. Mov Disord. 2011;26(4):664\u201370.","journal-title":"Mov Disord"},{"issue":"4","key":"963_CR18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00415-010-5793-z","volume":"258","author":"A Antonini","year":"2011","unstructured":"Antonini A, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol. 2011;258(4):579\u201385.","journal-title":"J Neurol"},{"issue":"6","key":"963_CR19","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/mds.28599","volume":"36","author":"FAP Nijhuis","year":"2021","unstructured":"Nijhuis FAP, Esselink R, de Bie RMA, Groenewoud H, Bloem BR, Post B, et al. Translating evidence to advanced Parkinson\u2019s disease patients: a systematic review and meta-analysis. Mov Disord. 2021;36(6):1293\u2013307.","journal-title":"Mov Disord"},{"key":"963_CR20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, Smilowska K, Berg D, Corvol JC, et al. European Academy of Neurology\/Movement Disorder Society-European Section Guideline on the treatment of Parkinson\u2019s disease: i. invasive therapies. Mov Disord. 2022;37:1360\u201374.","journal-title":"Mov Disord"},{"issue":"2","key":"963_CR21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"D Phillipo","year":"2018","unstructured":"Phillipo D, Ades A, Dias S, Palmer S, Abrams K, Welton N. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"key":"963_CR22","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: Methods for population-adjusted indirect comparisons in submission to NICE. 2016 [cited; Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2017\/05\/Population-adjustment-TSD-FINAL.pdf. Accessed: Dec 2021."},{"issue":"4","key":"963_CR23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500\u20139.","journal-title":"Mov Disord"},{"key":"963_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.06.002","volume":"29","author":"SE Palhagen","year":"2016","unstructured":"Palhagen SE, Sydow O, Johansson A, Nyholm D, Holmberg B, Widner H, et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson\u2019s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord. 2016;29:17\u201323.","journal-title":"Parkinsonism Relat Disord"},{"key":"963_CR25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtosek Z, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13\u201320.","journal-title":"Parkinsonism Relat Disord"},{"key":"963_CR26","volume-title":"Systematic reviews: CRD's guidance for undertaking reviews in healthcare","author":"Centre for Reviews and Dissemination","year":"2009","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in healthcare. University of York; 2009."},{"key":"963_CR27","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"963_CR28","doi-asserted-by":"crossref","DOI":"10.1002\/9781118951651","volume-title":"Network meta-analysis for decision making","author":"S Dias","year":"2018","unstructured":"Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Network meta-analysis for decision making. Wiley; 2018."},{"key":"963_CR29","doi-asserted-by":"crossref","unstructured":"Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ (editors). Chapter 7. Checking for Inconsistency. In: Network meta-analysis for decisionmaking, 1st ed. Wiley; 2018.","DOI":"10.1002\/9781118951651"},{"key":"963_CR30","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"key":"963_CR31","unstructured":"Sterne JAC, Hernan MA, McAleenan A, Reeves BC, Higgins JPT. Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available fromhttps:\/\/training.cochrane.org\/handbook"},{"key":"963_CR32","unstructured":"NIH. Study Quality Assessment Tools; 2021.[cited 7 November 2022]; Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed: 7 Nov 2022."},{"key":"963_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.parkreldis.2017.09.025","volume":"45","author":"RWK Borgemeester","year":"2017","unstructured":"Borgemeester RWK, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease patients with cognitive dysfunction: a retrospective long-term follow-up study. Parkinsonism Relat Disord. 2017;45:33\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"963_CR34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/mds.27283","volume":"33","author":"HS Dafsari","year":"2018","unstructured":"Dafsari HS, Silverdale M, Strack M, Rizos A, Ashkan K, Mahlstedt P, et al. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson\u2019s disease. Mov Disord. 2018;33(3):421\u201330.","journal-title":"Mov Disord"},{"issue":"3","key":"963_CR35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mds.27626","volume":"34","author":"HS Dafsari","year":"2019","unstructured":"Dafsari HS, Martinez-Martin P, Rizos A, Trost M, Dos Santos Ghilardi MG, Reddy P, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson\u2019s disease. Mov Disord. 2019;34(3):353\u201365.","journal-title":"Mov Disord"},{"issue":"8","key":"963_CR36","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.758","volume":"7","author":"O De Fabregues","year":"2017","unstructured":"De Fabregues O, Dot J, Abu-Suboh M, Hernandez-Vara J, Ferre A, Romero O, et al. Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion. Brain Behav. 2017;7(8): e00758.","journal-title":"Brain Behav"},{"issue":"9","key":"963_CR37","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med. 2006;355(9):896\u2013908.","journal-title":"N Engl J Med"},{"issue":"6","key":"963_CR38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","volume":"263","author":"S Drapier","year":"2016","unstructured":"Drapier S, Eusebio A, Degos B, Verin M, Durif F, Azulay JP, et al. Quality of life in Parkinson\u2019s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol. 2016;263(6):1111\u20139.","journal-title":"J Neurol"},{"issue":"9","key":"963_CR39","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/mds.26292","volume":"30","author":"D Floden","year":"2015","unstructured":"Floden D, Busch RM, Cooper SE, Kubu CS, Machado AG. Global cognitive scores do not predict outcome after subthalamic nucleus deep brain stimulation. Mov Disord. 2015;30(9):1279\u201383.","journal-title":"Mov Disord"},{"issue":"10","key":"963_CR40","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, et al. Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468\u201374.","journal-title":"Mov Disord"},{"issue":"2","key":"963_CR41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1212\/WNL.0000000000003485","volume":"88","author":"CS Kubu","year":"2017","unstructured":"Kubu CS, Cooper SE, Machado A, Frazier T, Vitek J, Ford PJ. Insights gleaned by measuring patients\u2019 stated goals for DBS: More than tremor. Neurology. 2017;88(2):124\u201330.","journal-title":"Neurology"},{"issue":"3","key":"963_CR42","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000475765","volume":"95","author":"D Li","year":"2017","unstructured":"Li D, Zhang C, Gault J, Wang W, Liu J, Shao M, et al. Remotely programmed deep brain stimulation of the bilateral subthalamic nucleus for the treatment of primary Parkinson disease: a randomized controlled trial investigating the safety and efficacy of a novel deep brain stimulation system. Stereotact Funct Neurosurg. 2017;95(3):174\u201382.","journal-title":"Stereotact Funct Neurosurg"},{"issue":"4","key":"963_CR43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord. 2015;30(4):510\u20136.","journal-title":"Mov Disord"},{"key":"963_CR44","doi-asserted-by":"crossref","unstructured":"Murata M, Mihara M, Hasegawa K, Beomseok J, Chon-Haw T, Nishikawa N, et al. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients. NPJ Parkinsons Dis. 2016;2:16020.","DOI":"10.1038\/npjparkd.2016.20"},{"issue":"3\u20134","key":"963_CR45","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.wneu.2010.06.015","volume":"75","author":"T Soulas","year":"2011","unstructured":"Soulas T, Sultan S, Gurruchaga JM, Palfi S, Fenelon G. Depression and coping as predictors of change after deep brain stimulation in Parkinson\u2019s disease. World Neurosurg. 2011;75(3\u20134):525\u201332.","journal-title":"World Neurosurg."},{"issue":"7","key":"963_CR46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(15)00087-3","volume":"14","author":"L Timmermann","year":"2015","unstructured":"Timmermann L, Jain R, Chen L, Maarouf M, Barbe MT, Allert N, et al. Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinson\u2019s disease (the VANTAGE study): a non-randomised, prospective, multicentre, open-label study. Lancet Neurol. 2015;14(7):693\u2013701.","journal-title":"Lancet Neurol"},{"issue":"4","key":"963_CR47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/imj.13754","volume":"48","author":"N Vijiaratnam","year":"2018","unstructured":"Vijiaratnam N, Hewer S, Varley S, Paul E, Bertram KL, Lee W, et al. Levodopa-carbidopa intestinal gel: is the naso-jejunal phase a redundant convention? Intern Med J. 2018;48(4):469\u201371.","journal-title":"Intern Med J"},{"issue":"1","key":"963_CR48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.brs.2015.08.005","volume":"9","author":"HS Dafsari","year":"2016","unstructured":"Dafsari HS, Reddy P, Herchenbach C, Wawro S, Petry-Schmelzer JN, Visser-Vandewalle V, et al. Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson\u2019s disease. Brain Stimul. 2016;9(1):78\u201385.","journal-title":"Brain Stimul"},{"key":"963_CR49","unstructured":"MRC Biostatistics Unit, University of Cambridge. DIC: Deviance Information Critera. [cited 7 November 2022]; Available from: https:\/\/www.mrc-bsu.cam.ac.uk\/software\/bugs\/the-bugs-project-dic\/ . Accessed: 7 Nov 2022."},{"issue":"5","key":"963_CR50","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/mds.23638","volume":"26","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Auinger P, Parkinson Study G. Determination of minimal clinically important change in early and advanced Parkinson\u2019s disease. Mov Disord. 2011;26(5):813\u20138.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"963_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horvath","year":"2017","unstructured":"Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, et al. Changes in quality of life in Parkinson\u2019s disease: how large must they be to be relevant? Neuroepidemiology. 2017;48(1\u20132):1\u20138.","journal-title":"Neuroepidemiology"},{"issue":"Suppl 1","key":"963_CR52","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/S1353-8020(13)70040-3","volume":"20","author":"MA van der Marck","year":"2014","unstructured":"van der Marck MA, Bloem BR. How to organize multispecialty care for patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(Suppl 1):S167\u201373.","journal-title":"Parkinsonism Relat Disord"},{"key":"963_CR53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1874205X01206010037","volume":"6","author":"SW Pedersen","year":"2012","unstructured":"Pedersen SW, Clausen J, Gregerslund MM. Practical guidance on how to handle levodopa\/carbidopa intestinal gel therapy of advanced PD in a Movement Disorder Clinic. Open Neurol J. 2012;6:37\u201350.","journal-title":"Open Neurol J"},{"issue":"6","key":"963_CR54","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"A Antonini","year":"2018","unstructured":"Antonini A, Moro E, Godeiro C, Reichmann H. Medical and surgical management of advanced Parkinson\u2019s disease. Mov Disord. 2018;33(6):900\u20138.","journal-title":"Mov Disord"},{"issue":"9","key":"963_CR55","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10072-019-03920-5","volume":"40","author":"E Olivola","year":"2019","unstructured":"Olivola E, Fasano A, Varanese S, Lena F, Santilli M, Femiano C, et al. Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease: causes of discontinuation and subsequent treatment strategies. Neurol Sci. 2019;40(9):1917\u201323.","journal-title":"Neurol Sci"},{"issue":"1","key":"963_CR56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s100720170062","volume":"22","author":"F Stocchi","year":"2001","unstructured":"Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson\u2019s disease: long-term results. Neurol Sci. 2001;22(1):93\u20134.","journal-title":"Neurol Sci"},{"issue":"5","key":"963_CR57","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","volume":"264","author":"A Sesar","year":"2017","unstructured":"Sesar A, Fernandez-Pajarin G, Ares B, Rivas MT, Castro A. Continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease: 10-year experience with 230 patients. J Neurol. 2017;264(5):946\u201354.","journal-title":"J Neurol"},{"issue":"6","key":"963_CR58","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1586\/ern.09.48","volume":"9","author":"A Antonini","year":"2009","unstructured":"Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson\u2019s disease: selection criteria and patient management. Expert Rev Neurother. 2009;9(6):859\u201367.","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"963_CR59","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s00415-018-8816-9","volume":"265","author":"A Tessitore","year":"2018","unstructured":"Tessitore A, Marano P, Modugno N, Pontieri FE, Tambasco N, Canesi M, et al. Caregiver burden and its related factors in advanced Parkinson\u2019s disease: data from the PREDICT study. J Neurol. 2018;265(5):1124\u201337.","journal-title":"J Neurol"},{"key":"963_CR60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/bs.irn.2017.03.001","volume":"132","author":"J Timpka","year":"2017","unstructured":"Timpka J, Nitu B, Datieva V, Odin P, Antonini A. Device-aided treatment strategies in advanced Parkinson\u2019s disease. Int Rev Neurobiol. 2017;132:453\u201374.","journal-title":"Int Rev Neurobiol"},{"key":"963_CR61","doi-asserted-by":"crossref","unstructured":"Santos-Garcia D, de Deus Fonticoba T, Suarez Castro E, Aneiros Diaz A, McAfee D. 5-2-1 Criteria: a simple screening tool for identifying advanced PD patients who need an optimization of Parkinson\u2019s treatment. Parkinsons Dis. 2020;2020:7537924.","DOI":"10.1155\/2020\/7537924"},{"key":"963_CR62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","volume":"92","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T, et al. Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord. 2021;92:59\u201366.","journal-title":"Parkinsonism Relat Disord"},{"issue":"suppl. 2","key":"963_CR63","first-page":"A628","volume":"34","author":"D Santos","year":"2019","unstructured":"Santos D, de Deus T, Su\u00e1rez Castro E, Aneiros A. Motor and non-motor symptoms burden, autonomy, quality of life and principal caregiver status is worse in patients with 5-2-1 positive criteria: a simple screening tool for identifying PD patients who need an optimization of Parkinson\u00b4s treatment. Mov Disord. 2019;34(suppl. 2):A628.","journal-title":"Mov Disord"},{"key":"963_CR64","doi-asserted-by":"crossref","unstructured":"Santos D, de Deus T, Su\u00e1rez E. EPR2071.Quality of life is worse in Parkinson\u2019s disease (PD) patients with 5-2-1 positive criteria: a simple screening tool for identifying advance PD cases who need an optimization of Parkinson\u2019s treatment. Eur J Neurol. 2019;26 (suppl.1):238.","DOI":"10.1155\/2020\/7537924"},{"key":"963_CR65","unstructured":"Tsuboi Y, Nakagawa R, Ishido M, Yoshinaga Y, Hashimoto T, Mishima T, et al. EPR3072. The quality of life burden in advanced Parkinson's disease applying \"5-2-1\" diagnosing criteria: subgroup\nanalyses of the JAQPAD (Japanese QOL survey of Parkinson's disease) study. Eur J Neurol. 2019;26 (suppl. 1):316."},{"issue":"1","key":"963_CR66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12883-020-1621-y","volume":"20","author":"D van Poppelen","year":"2020","unstructured":"van Poppelen D, Sisodia V, de Haan RJ, Dijkgraaf MGW, Schuurman PR, Geurtsen GJ, et al. Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson\u2019s disease\u2014the INfusion VErsus STimulation (INVEST) study. BMC Neurol. 2020;20(1):40.","journal-title":"BMC Neurol"},{"issue":"11","key":"963_CR67","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1002\/mds.28703","volume":"36","author":"E Freire-Alvarez","year":"2021","unstructured":"Freire-Alvarez E, Kur\u010da E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, et al. Levodopa-carbidopa intestinal gel reduces dyskinesia in Parkinson\u2019s disease in a randomized trial. Mov Disord. 2021;36(11):2615\u201323.","journal-title":"Mov Disord"},{"issue":"5","key":"963_CR68","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","volume":"21","author":"VC De Cock","year":"2022","unstructured":"De Cock VC, Dodet P, Leu-Semenescu S, Aerts C, Castelnovo G, Abril B, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson\u2019s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol. 2022;21(5):428\u201337.","journal-title":"Lancet Neurol"},{"issue":"8","key":"963_CR69","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/mds.28048","volume":"35","author":"JA Karl","year":"2020","unstructured":"Karl JA, Ouyang B, Goetz S, Metman LV. A novel DBS paradigm for axial features in Parkinson\u2019s disease: a randomized crossover study. Mov Disord. 2020;35(8):1369\u201378.","journal-title":"Mov Disord"},{"issue":"1","key":"963_CR70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41531-021-00194-7","volume":"7","author":"B Meira","year":"2021","unstructured":"Meira B, Degos B, Corsetti E, Doulazmi M, Berthelot E, Virbel-Fleischman C, et al. Long-term effect of apomorphine infusion in advanced Parkinson\u2019s disease: a real-life study. NPJ Parkinsons Dis. 2021;7(1):50.","journal-title":"NPJ Parkinsons Dis."},{"issue":"2","key":"963_CR71","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mds.28952","volume":"37","author":"I Todt","year":"2022","unstructured":"Todt I, Al-Fatly B, Granert O, Kuhn AA, Krack P, Rau J, et al. The contribution of Subthalamic Nucleus Deep Brain Stimulation to the improvement in motor functions and quality of life. Mov Disord. 2022;37(2):291\u2013301.","journal-title":"Mov Disord"},{"key":"963_CR72","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1212\/WNL.0000000000012246","volume":"97","author":"F Bove","year":"2021","unstructured":"Bove F, Mulas D, Cavallieri F, Castrioto A, Chabardes S, Meoni S, et al. Long-term outcomes (15 Years) after Subthalamic Nucleus Deep Brain Stimulation in patients with Parkinson disease. Neurology. 2021;97:e254\u201362.","journal-title":"Neurology"},{"issue":"8","key":"963_CR73","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00415-021-10430-y","volume":"268","author":"MA Volonte","year":"2021","unstructured":"Volonte MA, Clarizio G, Galantucci S, Scamarcia PG, Cardamone R, Barzaghi LR, et al. Long term follow-up in advanced Parkinson\u2019s disease treated with DBS of the subthalamic nucleus. J Neurol. 2021;268(8):2821\u201330.","journal-title":"J Neurol"},{"issue":"6","key":"963_CR74","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00702-020-02175-1","volume":"127","author":"A Antonini","year":"2020","unstructured":"Antonini A, Abbruzzese G, Berardelli A, Modugno N, Stroppa I, Tamma F, et al. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson\u2019s disease patients. J Neural Transm. 2020;127(6):881\u201391.","journal-title":"J Neural Transm"},{"issue":"7","key":"963_CR75","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mdc3.13239","volume":"8","author":"DG Standaert","year":"2021","unstructured":"Standaert DG, Aldred J, Anca-Herschkovitsch M, Bourgeois P, Cubo E, Davis TL, et al. DUOGLOBE: one-year outcomes in a real-world study of levodopa carbidopa intestinal gel for Parkinson\u2019s disease. Mov Disord Clin Pract. 2021;8(7):1061\u201374.","journal-title":"Mov Disord Clin Pract."},{"issue":"3","key":"963_CR76","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3233\/JPD-212979","volume":"12","author":"N Kovacs","year":"2022","unstructured":"Kovacs N, Bergmann L, Anca-Herschkovitsch M, Cubo E, Davis TL, Iansek R, et al. Outcomes impacting quality of life in advanced Parkinson\u2019s disease patients treated with levodopa-carbidopa intestinal gel. J Parkinsons Dis. 2022;12(3):917\u201326.","journal-title":"J Parkinsons Dis"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00963-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:05:57Z","timestamp":1670252757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00963-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":76,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00963-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"29 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study and its open access publication\u00a0was supported and funded by AbbVie Inc. AbbVie participated in study design, research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding Statement"}},{"value":"Angelo Antonini has received compensation for consultancy and speaker-related activities from UCB, Boehringer Ingelheim, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche. He receives research support from Chiesi Pharmaceuticals, Lundbeck, Bial, Horizon2020 Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation. He serves as consultant for Boehringer\u2013Ingelheim for legal cases on pathological gambling. Rajesh Pahwa has received consulting fees from AbbVie, ACADIA, Acorda, Adamas, Cynapsus, Global Kinetics, Lundbeck, Neurocrine, Pfizer, Sage, Sunovion, Teva Neuroscience and US World Meds. He has received research grants from AbbVie, Adamas, Avid, Biotie, Boston Scientific, Civitas, Cynapsus, Kyowa, National Parkinson Foundation, NIH\/NINDS, Parkinson Study Group. Per Odin has received compensations for consultancy and speaker-related activities from AbbVie, Bial, Britannia, Ever Pharma, Lobsor, Nordic Infucare, Stada, and Zambon. He has received royalties from Uni-Med Verlag. Stuart Isaacson has received honoraria for CME, consultant, research grants, and\/or promotional speaker on behalf of AbbVie, Acadia, Acorda, Adamas, Addex, Affiris, Alexva, Allergan, Amarantus, Amneal, Aptinyx, Axial, Axovant, Benevolent, Biogen, Britannia, Cadent, Cala, Cerecor, Cerevel, Cipla, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Impax, Impel, Intec Pharma, Ipsen, Jazz, Kyowa, Lundbeck, Merz, Michael J. Fox Foundation, Mitsubishi Tanabe, Neuralys, Neurocrine, Neuroderm, Parkinson Study Group, Pharma2B, Prilenia, Promentis, Revance, Roche, Sanofi, Sunovion, Sun Pharma, Supernus, Teva, Theravance, UCB. Aristide Merola has received grant support from the NIH (KL2 TR001426). He has received speaker honoraria or advisory board honoraria from CSL Behring, AbbVie, Abbott, Medtronic, Theravance, and Cynapsus Therapeutics. He has received grant support from Lundbeck and AbbVie. Lin Wang, Lakshmi P. Kandukuri, Ali Alobaidi, Yanjun Bao, Cindy Zadikoff, Juan Carlos Parra, Lars Bergmann, and Connie H. Yan are employees of AbbVie and may own stocks\/shares in the company. K. Ray Chaudhuri has received educational funding from UCB, and honoraria for sponsored symposia from UCB, AbbVie, Britannia, US Worldmeds, Otsuka, Medtronic, Zambon and acted as a consultant for AbbVie, UCB, Britannia, Medtronic, and Mundipharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}},{"value":"As this is a retrospective study with anonymous data, no Ethics Committee or Institutional Review Board approvals were needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"As this is a retrospective study with anonymous data, no patient consent was needed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All data included in this analysis are in the public domain in the individual published studies.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All authors meet the ICMJE criteria for authorship, and have contributed to the development of the manuscript, and read and approved the final version for submission and agree to be accountable for the work. The concept of the article was provided by Angelo Antonini, Yash J. Jalundhwala and Lin Wang. Lin Wang and Prasanna L. Kandukuri provided the data analysis.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}